1832 Asset Management’s United Therapeutics UTHR Stock Holding History

1832 Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.06M	Sell	6,844 -4,038	-37%	-$2.01M	﹤0.01%	449
2025 Q4	$5.3M	Buy	10,882 +6,427	+144%	+$2.99M	﹤0.01%	434
2025 Q3	$1.87M	Sell	4,455 -525	-11%	-$177K	﹤0.01%	511
2025 Q2	$1.43M	Sell	4,980 -292	-6%	-$87.3K	﹤0.01%	539
2025 Q1	$1.63M	Sell	5,272 -186	-3%	-$63.7K	﹤0.01%	510
2024 Q4	$1.93M	Buy	5,458 +211	+4%	+$77.6K	﹤0.01%	497
2024 Q3	$1.88M	Buy	5,247 +343	+7%	+$116K	﹤0.01%	539
2024 Q2	$1.56M	Buy	+4,904	New	+$1.3M	﹤0.01%	536
2018 Q3	–	Sell	-30	Closed	-$4K	–	720
2018 Q2	$4K	Hold	30	–	–	﹤0.01%	618
2018 Q1	$3K	Sell	30 -185	-86%	-$23.5K	﹤0.01%	643
2017 Q4	$32K	Sell	215 -295	-58%	-$37.5K	﹤0.01%	571
2017 Q3	$60K	Buy	510 +18	+4%	+$2.3K	﹤0.01%	569
2017 Q2	$64K	Buy	492 +12	+3%	+$1.5K	﹤0.01%	540
2017 Q1	$65K	Sell	480 -670	-58%	-$102K	﹤0.01%	579
2016 Q4	$166K	Buy	+1,150	New	+$147K	﹤0.01%	627

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

1832 Asset Management's UTHR Position: Q1 2026 in Review

1832 Asset Management reduced its United Therapeutics (UTHR) stake by 37% in Q1 2026, selling an estimated $2.01M and leaving 6,844 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #449.

1832 Asset Management first reported a position in UTHR in Q4 2016 and has held it in 15 quarters since. The position peaked at $5.3M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

1832 Asset Management held 6,844 shares of United Therapeutics worth $4.06M as of Q1 2026.
1832 Asset Management sold 4,038 United Therapeutics shares in Q1 2026, an estimated $2.01M.
United Therapeutics made up ﹤0.01% of 1832 Asset Management's portfolio in Q1 2026, its #449 holding.
1832 Asset Management first reported a position in United Therapeutics in Q4 2016 and has held it in 15 quarters since.
1832 Asset Management's United Therapeutics position peaked at $5.3M in Q4 2025.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.